section name header

Pronunciation ⬇

toe-PEER-i-mate audio

Indications ⬆ ⬇

REMS

Unlabeled Use:

Action ⬆ ⬇

Therapeutic Effects:

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed (80%) after oral administration.

Distribution: Unknown.

Metabolism/Excretion: 70% excreted unchanged in urine.

Half-life: 21 hr; Extended-release — 31 hr.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, oligohydrosis (↑ in children).

EENT: abnormal vision, diplopia, nystagmus, acute myopia/secondary angle closure glaucoma, ↑ intraocular pressure, mydriasis, ocular pain, ocular redness, retinal detachment, visual field defects.

F and E: hyperchloremic metabolic acidosis.

GI: nausea, abdominal pain, anorexia, constipation, dry mouth, encephalopathy, hyperammonemia.

GU: kidney stones.

Hemat: BLEEDING, leukopenia.

Metab: weight loss, hyperthermia (↑ in children).

Neuro: ataxia, paresthesia, tremor , SEIZURES, SUICIDAL THOUGHTS, cognitive disorders, dizziness, drowsiness, fatigue, impaired concentration/memory, nervousness, psychomotor slowing, speech problems, sedation, aggressive reaction, agitation, anxiety, confusion, depression, malaise, mood problems.

Misc: fever.

Interactions ⬆ ⬇

Drug-Drug:

Route/Dosage ⬆ ⬇

see Calculator

Epilepsy (monotherapy)

Renal Impairment

Epilepsy (adjunctive therapy)

Renal Impairment

Migraine Prevention

Renal Impairment

Implementation ⬆ ⬇

US Brand Names ⬆ ⬇

Qudexy XR, Topamax, Topamax Sprinkle, Trokendi XR

Classifications ⬆ ⬇

Therapeutic Classification: anticonvulsants

Availability ⬆ ⬇

(Generic available)

Time/Action Profile ⬆ ⬇

(blood levels†)

ROUTEONSETPEAKDURATION
POunknown2 hr12 hr
PO-ERunknown24 hrunknown

†After single dose.

Assessment ⬆ ⬇

Lab Test Considerations:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Code ⬆

NDC Code*